24小时热门版块排行榜    

查看: 411  |  回复: 0

liushuai8608

木虫 (小有名气)

[求助] 医学类干细胞与关节炎临床实验设计

41. IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee..
1) Agency &Identifier
Agency: D.B.F. Saris, UMC Utrecht
(First received: January 13, 2014  Last updated: July 17, 2014  Last verified: July 2014)
Identifier:NCT02037204
2) Purpose
Articular cartilage defects in the knee have a poor intrinsic healing capacity and may lead to functional disability and osteoarthritis. Cartilage cell therapy using autologous chondrocyte implantation (ACI) has been established as the first advanced treatment therapy medicinal product. Although this technique has achieved good mid-term results, it is a costly and extensive two-stage procedure which is limited by the number of chondrocytes obtained by biopsy and the dedifferentiation resulting from the expansion phase. Therefore, there is a need for improvement. A new cartilage repair technique should aim at decreasing surgical trauma, lowering complexity, improving logistics and cost-effectiveness while retaining or improving clinical outcome. Direct contact between mesenchymal stromal cells (MSCs) and dedifferentiated articular chondrocytes in vitro showed improvement of the chondrogenic phenotype of dedifferentiated articular chondrocytes. In addition, preserving the pericellular matrix of chondrocytes improves cartilage formation. These chondrons (chondrocytes with their pericellular matrix) have shown improved cartilage formation when combined with allogeneic MSCs in extensive preclinical studies. The cells are mixed with fibrin cell carrier and applied to the cartilage lesion within one surgical procedure. This will reduce patient morbidity and improve patient care through immediate transplantation of a potent cell-based cartilage product. This is a phase I/II prospective monocenter study to evaluate the safety and feasibility of the IMPACT for treatment of focal articular cartilage lesions of the knee.
Condition        Intervention        Phase
Foreign-Body Reaction
Inflammation
Effusion (L) Knee
Knee Pain Swelling        Other: Cartilage repair surgery        Phase 1
Phase 2

Arms        Assigned Interventions
Experimental: Cartilage repair surgery
Single-stage cartilage repair surgery using autologous chondrons and allogeneic MSCs in a fibrin glue carrier.        Other: Cartilage repair surgery
Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
Other Names:
Single-stage
Cartilage repair
IMPACT

3) Criteria
Inclusion Criteria:
•        Age >18 and <45 years old
•        Symptomatic isolated full-thickness articular cartilage lesion on the femoral condyle or trochlea.
•        Size 2 - 8 cm2
•        Intact anterior cruciate ligament
Exclusion Criteria:
•        (History of) osteoarthritis, defined as Kellgren-Lawrence grade >3 as determined from appropriate X-ray.
•        Concomitant inflammatory disease that affects the joint (rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis)
•        (History of) Septic arthritis.
•        Malalignment requiring an osteotomy.
•        (History of) total menisectomy in the target knee joint.
•        Any surgery in the knee joint 6 months prior to study inclusion.
•        Risk groups for MRI scanning due to the magnetic field like patients with pacemakers, nerve stimulators, metal particles, stents, clips or implants, (possible) pregnancy or breast feeding.
•        Patients with severe anxiety for MRI scans and/or needles

4) Outcome Measures
Primary Outcome Measures:
•        Safety [ Time Frame: Multiple time points up to 18 months ] [ Designated as safety issue: Yes ]
Adverse event rate non-inferior to standard treatment (autologous chondrocyte implantation) and leads to no serious adverse events such as a immunological response.


Secondary Outcome Measures:
•        Clinical improvement [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Clinical improvement as measured by patient reported outcome scores.

Other Outcome Measures:
•        Structural repair [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To examine parameters of structural repair at one year after treatment using MRI and a second-look arthroscopy.

•        Health care use and costs [ Time Frame: 18 months ] [ Designated as safety issue: No ]
To assess the healthcare use and costs related to the procedure as well as the health-related work leave during the study period.
只要开始行动就会有成功的希望
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 liushuai8608 的主题更新
信息提示
请填处理意见